| 1/66 | US=114 / Tese/FAP Campos HGA. Estudo morfológico e imunoistoquímico das anomalias vasculares da infância. São Paulo, 2005. 108 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2005/us114.pdf HEMANGIOMA. PATOLOGIA; APOPTOSE; CRIANCA; ANGIOGENESE PATOLOGICA; IMUNOHISTOQUIMICA |
| 2/66 | US=121 / Tese/FAP Sato Y. A análise da expressão de c-erbB-2, EGFR, VEGF e ciclinas em carcinoma epidermóide do esôfago. São Paulo, 2005. 106 p. Dissertação(Mestrado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2005/YukieSato/YukieSatomestrado.pdf CANCER DO ESOFAGO. GENETICA; CANCER DO ESOFAGO. PATOLOGIA; CARCINOMA EPIDERMOIDE; RECEPTORES DE FATORES DE CRESCIMENTO; RECEPTORES C-ERBB-2; CICLINAS |
| 3/66 | US=201 / Tese/FAP Pinto GLS. Análise imunoistoquímica da expressão de COX-2 e VEGF em alterações proliferativas endometriais em tissue microarrays. São Paulo, 2007. 62 p. Dissertação(Mestrado)-Fundação Antônio Prudente. Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2007/GabrielLowndesSouzaPinto/GabrielLowndesSouzaPintomestrado.pdf CANCER DO ENDOMETRIO; HIPERPLASIA ENDOMETRIAL; IMUNOHISTOQUIMICA; CICLOOXIGENASE 2; POLIPOS; TISSUE MICRO ARRAY |
| 4/66 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Protein kinase structure, function, and regulation. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 75-117. ISBN 978-0-470-22965-1. QUINASE; QUINASE. ESTRUTURA; RECEPTORES TIROSINA QUINASE (RTK); FATOR DE CRESCIMENTO EPIDERMICO (EGF); INSULINA; IGF1; IGF1R; FATORES DE CRESCIMENTO DE FIBROBLASTOS (FGF); FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ANGIOPOIETINA-2; EPHRIN; DOMINIO TRANSMEMBRANA; QUINASE. FUNCAO; PROTEINA QUINASE. ATIVIDADE CATALITICA; PROTEINA QUINASE. CARACTERIZACAO CINETICA; PROTEINA QUINASE. QUIMICA DE CATALISE; PROTEINA QUINASE. REGULACAO; REGULACAO VIA FOSFORILACAO; REGULACAO POR N-TERMINAL; FAMILIA QUINASE SRC; QUINASE DE ADESAO FOCAL (FAK); QUINASES CICLINA-DEPENDENTES (CDK) |
| 5/66 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Receptor tyrosine kinases. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 119-213. ISBN 978-0-470-22965-1. RECEPTORES DA TIROSINA QUINASE (RTK); FATOR DE CRESCIMENTO EPIDERMICO; CANCER; FATOR DE CRESCIMENTO INSULIN-LIKE (IGF); QUINASE DO LINFOMA ANAPLASICO (ALK); FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); FATOR DE CRESCIMENTO DERIVADO DE PLAQUETAS (PDGF); TUMORES ESTROMAIS GASTROINTESTINAIS; SINDROME HIPEREOSINOFILICA; GLIOBLASTOMA; TUMOR MALIGNO DA BAINHA DE NERVO PERIFERICO; EOSINOFILIA; DERMATOFIBROSARCOMA PROTUBERANS; PERICITO; FATOR DE CRESCIMENTO FIBROBLASTICO; KIT; MASTOCITOSE; CANCER DE PULMAO DE PEQUENAS CELULAS; MELANOMA; LEUCEMIA MIELOIDE AGUDA; LINFOMA NASOSSINUSAL; TUMORES TESTICULARES DE CELULAS GERMINATIVAS; FLT3; LEUCEMIA; RET; CARCINOMA DE TIREOIDE; MET; RON |
| 6/66 | US=9 / Urologia Bocci G, Pasqualetti G, Di Paolo A, Crea F, Del Tacca M, Danesi R. Pharmacogenetics of angiogenesis. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 233-42. ISBN 978-1-60327-831-7. TERAPIA ANTIANGIOGENESIS; RISCO DE CANCER; POLIMORFISMOS DE NUCLEOTIDEO UNICO; HIF; MMP; TNF; VEGF |
| 7/66 | US=3 / Radioterapia Wheeler DL, Hoang T, Harari PM. Contributions of targeted agents. In: Harari PM, Connor NP, Grau C. Functional preservation and quality of life in head and neck radiotherapy. New York: Springer, 2009. p. 215-23. (Medical radiology/Radiation oncology) ISBN 978-3-540-73231-0. AGENTES ALVO; CABECA E PESCOCO; CARCINOMA DE CELULAS ESCAMOSAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); BEVACIZUMABE; TOXICIDADE; QUALIDADE DE VIDA |
| 8/66 | US=5 / Biol/Mol Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 51-81. (Recent results in cancer research) ISBN 978-3-540-78280-3. INIBICAO DA ANGIOGENESE; TRATAMENTO DO CANCER; FATOR DE CRESCIMENTO DERIVADO DE PLAQUETAS (PDGF); FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF) |
| 9/66 | US=5 / Biol/Mol Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical phase III and beyond. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 137-63. (Recent results in cancer research) ISBN 978-3-540-78280-3. ESTUDOS CLINICOS DE FASE III; ANTICORPO ANTI-VEGF; BEVACIZUMABE; AFLIBERCEPT; SORAFENIBE; SUNITINIBE; AXITINIBE; CEDIRANIBE; VANDETANIBE; VATALANIBE; ENDOSTATINA; TALIDOMIDA |
| 10/66 | US=5 / Biol/Mol Gerber HP, Olazoglu E, Grewal IS. Targeting inflammatory cells to improve anti-VEGF therapies in oncology. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 185-200. (Recent results in cancer research) ISBN 978-3-540-78280-3. SEGMENTACAO CELULAS INFLAMATORIAS; ANTI-VEGF; TRATAMENTO DO CANCER; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); CELULAS PROGENITORAS ENDOTELIAIS; MACROFAGOS ASSOCIADOS AO TUMOR; LINFOCITOS; MASTOCITOS; NEUTROFILOS |
| 11/66 | US=22 / Urologia Bukowski RM, Figlin RA, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma: overview. In: ___. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 1-12. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; VHL GENE; PROTEINA VHL; VEGF; PDGF; TERAPIAS RCC |
| 12/66 | US=22 / Urologia Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2. VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR |
| 13/66 | US=22 / Urologia Rathmell WK, Rini BI. VEGF: biologic aspects and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 99-118. ISBN 978-1-58829-737-2. |
| 14/66 | US=22 / Urologia Lam JS, Figlin RA, Belldegrum AS,. VEGF: and PDGF receptors: biologic relevance and clinical approaches to inhibition. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 119-49. ISBN 978-1-58829-737-2. DERIVADO DE PLAQUETAS FACTOR DE CRESCIMENTO; RECEPTORES; TRANSDUCAO DE SINAL; TIROSINA-QUINASE; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR |
| 15/66 | US=22 / Urologia George S, Bukowski RM. Sorafenib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 167-87. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; SORAFENIB; INIBIDOR DE TIROSINA CINASE; VEGF; TERAPIA ANTIANGIOGENICA |
| 16/66 | US=22 / Urologia Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2. INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB |
| 17/66 | US=22 / Urologia Shaheen PE, Bukowski RM, Finke JH. The role of gangliosides in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 405-23. ISBN 978-1-58829-737-2. GANGLIOSIDEOS NA RCC; GLICOESFINGOLIPIDOS; GANGLIOSIDOS E VEGF; GANGLIOSIDEOS COMO ALVOS TERAPEUTICOS |
| 18/66 | US=33 / Câncer Varner JA. Stem cells, angiogenesis, and neurogenesis in tumors. In: Bagley RG, Teicher BA. Stem cells and cancer. New York: Humana Press, 2009. p. 247-52. ISBN 978-1-60327-932-1. ANGIOGENESE; NEUROGENESE; NETRIN; SEMAFORINA; VEGF; NEUROPILINA; CELULAS PROGENITORAS |
| 19/66 | US=50 / Câncer Neeb A, Sleeman JP. Tumor lymphangiogenesis: what we know and don't know. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 93-104. ISBN 978-1-60327-086-1. LINFANGIOGENESE TUMOR; METASTASE; LINFANGIOGENESE; LINFONODO; VEGFR-3; VEGF-C; VEGF-D |
| 20/66 | US=50 / Câncer Detmar M. Tumor and lymph node lymphangiogenesis. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 255-61. ISBN 978-1-60327-086-1. TUMOR; LINFANGIOGENESE LINFONODO; CANCER; LINFANGIOGENESE; METASTASE LINFATICA; VEGF-A; VEGF-C; VEGFR-3; ANGIOGENESE |
